Preparation and characterization of ascorbic acid loaded solid lipid nanoparticles and investigation of their apoptotic effects

Colloids and Surfaces B: Biointerfaces

Volumn 121, Issue , 2014, Pages 270-280

  Güney, Gamze ^a   Kutlu, H Mehtap ^b   Genç, Lütfi ^b  

^a SAKARYA UNIVERSITY   (Turkey)

^b ANADOLU UNIVERSITY   (Turkey)

Author keywords

Apoptotic effect; Ascorbic acid (AA); Cancer; Cytotoxic activity; Solid lipid nanoparticles (SLNs)

Indexed keywords

CELLS; CYTOLOGY; DRUG PRODUCTS; NANOPARTICLES; TRANSMISSION ELECTRON MICROSCOPY;

APOPTOTIC EFFECTS; CANCER; CONFOCAL LASER SCANNING MICROSCOPY; CYTOTOXIC ACTIVITIES; HIGH ENTRAPMENT EFFICIENCIES; INDUCED APOPTOSIS; SOLID LIPID NANOPARTICLE (SLN); SOLID LIPID NANOPARTICLES;

ASCORBIC ACID;

ASCORBIC ACID; CASPASE 3; LIPOCORTIN 5; SOLID LIPID NANOPARTICLE; LIPID; NANOPARTICLE; PROPIDIUM IODIDE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; H RAS PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

3T3 CELL LINE; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CELL STRAIN; CELL STRAIN H RAS 5RP7; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SYNTHESIS; DRUG TUMOR LEVEL; ENZYME ASSAY; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SUSTAINED RELEASE FORMULATION; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CELL SURVIVAL; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG EFFECTS; METABOLISM; REPRODUCIBILITY; STATIC ELECTRICITY; TUMOR CELL LINE; ULTRASTRUCTURE; ANTINEOPLASTIC ACTIVITY; BIOACCUMULATION; CANCER CELL LINE; CELL ASSAY; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; DRUG FORMULATION; DRUG STABILITY; DRUG UPTAKE; FIBROBLAST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NANOANALYSIS; NANOENCAPSULATION; STRUCTURE ANALYSIS; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

ANIMALS; ANNEXIN A5; APOPTOSIS; ASCORBIC ACID; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; LIPIDS; MICE; MICROSCOPY, CONFOCAL; NANOPARTICLES; NIH 3T3 CELLS; PARTICLE SIZE; PROPIDIUM; RATS; REPRODUCIBILITY OF RESULTS; STATIC ELECTRICITY;

EID: 84905385152     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2014.05.008     Document Type: Article

References (56)

1. Peppas L., Blanchette J.O. Adv. Drug Deliv. Rev. 2004, 56:1649-1659.
2. Hu Jack C., Aryal S., Zhang L. Therap. Deliv. 2010, 1(2):323-334.
3. Szent-Györgyi A. Biochem. J. 1928, 22:1387-1409.
4. Spielholz C., Golde D.W., Houghton A.N., Nualart F., Ve Vera J.C. Cancer Res. 1997, 57:2529-2537.
5. Padayatty S.J., Riordan H.D., Hewitt S.M., Katz A., Hoffer L.J., Levine M. Can. Med. Assoc. J. 2006, 174(7):937-942.
6. Padayatty S.J., Sun H., Wang Y., Riordan H.D., Hewitt S.M., Katz A., Wesley R.A., Levine M. Ann. Intern. Med. 2004, 140(7):533-538.
7. Agus D.B., Vera J.C., Golde D.W. Cancer Res. 1999, 59:4555-4558.
8. Lupulescu A. Exp. Toxicol. Pathol. 1992, 44(1):3-9.
9. Buettner G.R., Moseley P.L. Free Radic. Res. Commun. 1993, 19:89-93.
10. Verrax J., Taper H., Calderon P. Curr. Mol. Pharmacol. 2008, 1:80-92.
11. Astuya A., Caprile T., Castro M., Salazar K., Garcia M., Reinicke K., Rodriguez F., Vera J.C., Millan C., Ulloa V., Low M., Martinez F., Nualart F. J. Neurosci. Res. 2005, 79:146-156.
12. Lawson S. J. Orthomol. Med. 2003, 18(3&4):173-186.
13. Iqbal K., Khan A., Khattak M.M. Pak. J. Nutr. 2004, 3(1):5-13.
14. Chen Q., Espey M.G., Krishna M.C., Mitchell J.B., Corpe C.P., Buettner G.R., Shacter E., Levine M. Proc. Natl. Acad. Sci. 2005, 102(38):13604-13609.
15. ®). Handbook of Pharmaceutical Controlled Release Technology 2000, 359-376. Marcel Dekker, New York. 2nd ed. D. Wise D (Ed.).
16. Muller R.H., Karsten M., Sven G. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
17. Muller R.H., Keck C.M. J. Biotech. 2004, 113:151-170.
18. Muller R.H., Lippacher A., Gohla S. Solid lipid nanoparticles (SLN) as carrier system for the controlled release of drugs. Handbook of Pharmaceutical Controlled Release Technology 2000, 377-391. Marcel Dekker, New York. D. Wise D (Ed.).
19. Mukherjee S., Ray S., Thakur R.S. Indian J. Pharm. Sci. 2009, 71(4):349-358.
20. Muller R.H., Mehnert W., Souto E.B. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for Dermal Delivery 2005, 719-738. Marcel Dekker, New York. L. Bronaugh (Ed.).
21. Muller R.H., Runge S.A. Solid lipid nanoparticles (SLN) for controlled drug delivery. Submicron Emulsions in Drug Targeting and Delivery 1998, 219-234. Harwood Academic Publishers, Amsterdam. Benita (Ed.).
22. Muller R.H. Colloidal carriers for controlled drug delivery and targeting: Modification. characterization and in vivo distribution 1991, 45-55. CRC Press.
23. Muller R.H., Mehnert W., Lucks J.S. Eur. J. Pharm. Biopharm. 1995, 41:62.
24. Lippacher A., Muller R.H., Mader K. Int. J. Pharm. 2001, 214:9-12.
25. R.H. Muller, J.S. Lucks, European Patent EP0605497 (1996).
26. Koppel D.E. J. Chem. Phys. 1972, 57:4814.
27. ICH Topic Q2B Validation of Analytical Procedures: Methodology 1996, The European Agency for the evaluation of medicinal products, CPMP/ICH/281/95, Step 4, Consensus Guideline.
28. Mossman T. J. Immunol. Methods 1983, 65:55-63.
29. Hahn W.C., Weinberg R.A. Nat. Rev. Cancer 2002, 2:331-341.
30. Hanahan D., Weinberg R.A. Cell 2002, 100:57-70.
31. Nie S., Xing Y., Kim G.J., Simons J.W. Annu. Rev. Biomed. Eng. 2007, 9(12):1-32.
32. Cameron E., Campbell A. Chem.-Biol. Interact. 1974, 9:258-315.
33. Cameron E., Pauling L. Proc. Natl. Acad. Sci. U.S.A. 1976, 73(10):3685-3689.
34. Cameron E., Pauling L., Leibovitz B. Cancer Res. 1979, 39:663-681.
35. Riordan H.D., Jackson J.A., Riordan N.H., Schultz M. J. Orthomol. Med. 1990, 5:72-73.
36. Riordan N.H., Riordan H.D., Meng X., Li Y., Jackson J.A. Med. Hyp. 1995, 44(3):207-213.
37. Padayatty S.J., Katz A., Wang Y., Eck P., Kwon O., Lee J., Chen S., Corpe C., Dutta A., Dutta S.K., Levine M. J. Am. College Nutr. 2003, 22(1):18-35.
38. Padayatty S., Levine M. J. Am. College Nutr. 2000, 19(4):423-425.
39. Hoffer L.J., Levine M., Assouline S., Melnychuk D., Padayatty S.J., Rosadiuk K., Rousseau C., Robitaille L., Miller W.H. Ann. Oncol. 2008, 19(11):1969-1974.
40. Prokop A., Davidson J.M. J. Pharm. Sci. 2008, 97:3518-3590.
41. Wissing S.A., Kayser O., Muller R.H. Adv. Drug Deliv. Rev. 2004, 56(9):1257-1272.
42. Souto E.B., Muller R.H. Lipid Nanoparticles (SLN and NLC) for Cosmetic, Dermal and Transdermal Applications 2007, 213-235. Informa Healthcare USA, New York. D. Thassu, M. Deleers, Y. Pathak, A. Domb (Eds.).
43. Muller R.H., Mehnert W., Souto E.B. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for dermal delivery 2005, Marcel Dekker, Inc., New York, Basel, Hong Kong, pp. 719-738.
44. Hou D., Xie C., Huang K., Zhu C. Biomaterials 2003, 24:1781-1785.
45. Lu B., Xiong S., Yang H., Yin X., Chao R. Eur. J. Pharm. Sci. 2006, 1403:1-10.
46. Alhaj N.A., Abdullah R., Ibrahim S., Bustamam A. Am. J. Pharmacol. Toxicol. 2008, 3(3):219-224.
47. Brioschi A., Zara P.G., Calderoni S., Gasco R.M., Mauro A. Molecules 2008, 13:230-254.
48. Serpe L., Catalano G.M., Cavalli R., Ugazio E., Bosco O., Canaparo R., Muntoni E., Frairia R., Gasco R.M., Eandi M., Zara P.G. Eur. J. Pharm. Biopharm. 2004, 58:673-680.
49. Zhu R.R., Qin L.L., Wang M., Wu S.M., Wang S.L., Zhang R., Liu Z.X., Sun X.Y., Yao S.D. Nanotechnology 2009, 20:1-7.
50. Sun J., Bi C., Chan H.M., Sun S., Zhang Q., Zheng Y. Colloids Surf. B: Biointerfaces 2013, 11:367-375.
51. Gokce E.H., Korkmaz E., Dellera E., Sandri G., Bonferoni M.C., Ozer O. Int. J. Nanomed. 2012, 7:1841-1850.
52. Yassin A.E., Anwer K., Mowafy H.A., Bagory I., Bayomi M.A., Alsarra I.A. Int. J. Med. Sci. 2010, 7(6):398-408.
53. Battaglia L., Serpe L., Muntoni E., Zara G., Trotta M., Gallarate M. Nanomedicine 2011, 6(9):1561-1573.
54. Kutlu H.M., Genç L., Güney G. Curr. Nanosci. 2013, 9:698-703.
55. Genç L., Kutlu H.M., Güney G. Pharm. Dev. Technol. 2013, 1-8. (early online).
56. Genç L. Pharm. Dev. Technol. 2014, 19(6):671-676.